M
Moderna Inc (MRNA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$215.27
-8.10 (-3.63%)
Market Cap: $90.38B
Last updated: Nov 17, 2026 at 11:06 AM ET
Moderna Inc (MRNA) Valuation Multiples
Moderna (MRNA) trades at 34.2x sales and 12.6x book value. Its P/S of 34.2x is above its 5-year median of 4.4x. Its forward P/E is 23.0x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 23.0x |
| Price to sales | 34.2x |
| Price to book | 12.6x |
| PEG | N/A |
| FCF yield | -2.3% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 34.2x | 4.4x | N/A |
| P/B | 12.6x | 2.7x | N/A |
Valuation History
Over the 8 year ends shown, its P/S ranged from 3.7x in 2022 to 107.8x in 2019.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $29.49 | N/A | 5.9x | 1.3x |
| 2024 | $41.58 | N/A | 4.9x | 1.5x |
| 2023 | $99.45 | N/A | 5.6x | 2.8x |
| 2022 | $179.62 | 9.0x | 3.7x | 3.8x |
| 2021 | $253.98 | 9.0x | 5.7x | 7.7x |
| 2020 | $104.47 | N/A | 51.3x | 16.2x |
| 2019 | $19.56 | N/A | 107.8x | 5.6x |
| 2018 | $15.27 | N/A | 39.9x | 3.3x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MRNA
What is MRNA's forward P/E ratio?
Moderna has a forward P/E ratio of 23.0x.
Is MRNA stock overvalued?
GNG's valuation label for MRNA is Overvalued.
What is MRNA's price to sales ratio?
Moderna has a price to sales ratio of 34.2x.
MRNA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors